Reference
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA
Cancer J Clin. 2021 Jan;71(1):7-33.
2. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer.
Lancet. 2019 Mar 23;393(10177):1240-53.
3. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al.
Ovarian cancer. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79.
4. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous
Recombination Deficiency: Exploiting the Fundamental Vulnerability of
Ovarian Cancer. Cancer Discov. 2015 Nov;5(11):1137-54.
5. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W,
Pujade-Lauraine E, et al. The impact of second to sixth line therapy on
survival of relapsed ovarian cancer after primary taxane/platinum-based
therapy. Ann Oncol. 2012 Oct;23(10):2605-12.
6. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza
AM, et al. Olaparib tablets as maintenance therapy in patients with
platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation
(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled,
phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-84.
7. Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S,
Follana P, et al. Niraparib Maintenance Therapy in Patients With
Recurrent Ovarian Cancer After a Partial Response to the Last
Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol.
2019 Nov 10;37(32):2968-73.
8. McMullen M, Karakasis K, Madariaga A, Oza AM. Overcoming Platinum and
PARP-Inhibitor Resistance in Ovarian Cancer. Cancers (Basel). 2020 Jun
17;12(6).
9. Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, et al. An Open-label,
Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with
Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian
Cancer. Clin Cancer Res. 2021 May 1;27(9):2452-8.
10. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent
ovarian cancer: latest evidence and clinical potential. Ther Adv Med
Oncol. 2014 Sep;6(5):229-39.
11. Bookman MA. Extending the platinum-free interval in recurrent
ovarian cancer: the role of topotecan in second-line chemotherapy.
Oncologist. 1999;4(2):87-94.
12. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M,
Thigpen T, et al. Definitions for response and progression in ovarian
cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the
Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011
Feb;21(2):419-23.
13. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS,
et al. Sequence variant classification and reporting: recommendations
for improving the interpretation of cancer susceptibility genetic test
results. Hum Mutat. 2008 Nov;29(11):1282-91.
14. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.
Standards and guidelines for the interpretation of sequence variants: a
joint consensus recommendation of the American College of Medical
Genetics and Genomics and the Association for Molecular Pathology. Genet
Med. 2015 May;17(5):405-24.
15. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et
al. Niraparib monotherapy for late-line treatment of ovarian cancer
(QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet
Oncol. 2019 May;20(5):636-48.
16. Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh
MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in
germline BRCA1/2 mutation carriers with advanced ovarian cancer and
three or more lines of prior therapy. Gynecol Oncol. 2016
Feb;140(2):199-203.
17. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher
EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib
in patients with high-grade ovarian carcinoma and a germline or somatic
BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and
ARIEL2. Gynecol Oncol. 2017 Nov;147(2):267-75.
18. Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, 3rd,
Bidzinski M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients
With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2
Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020 Apr
10;38(11):1164-74.
19. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma
(ARIEL2 Part 1): an international, multicentre, open-label, phase 2
trial. Lancet Oncol. 2017 Jan;18(1):75-87.
20. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et
al. ”BRCAness” syndrome in ovarian cancer: a case-control study
describing the clinical features and outcome of patients with epithelial
ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol.
2008 Dec 1;26(34):5530-6.
21. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay
V, et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian
cancer in the setting of PARP inhibitor resistance: a
multi-institutional study. Clin Cancer Res. 2013 Oct 1;19(19):5485-93.
22. Brann R, Kremer KM, Carlson M, LoCoco S, Lea JS, Miller DS, et al.
Outcomes of ovarian cancer patients treated with platinum or
non-platinum based chemotherapy after PARP inhibitor maintenance.
Journal of Clinical Oncology. 2021 2021/05/20;39(15_suppl):5563-.
23. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin
G, et al. Olaparib maintenance therapy in patients with
platinum-sensitive relapsed serous ovarian cancer: a preplanned
retrospective analysis of outcomes by BRCA status in a randomised phase
2 trial. Lancet Oncol. 2014 Jul;15(8):852-61.
24. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin
G, et al. Overall survival in patients with platinum-sensitive recurrent
serous ovarian cancer receiving olaparib maintenance monotherapy: an
updated analysis from a randomised, placebo-controlled, double-blind,
phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-89.
25. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian
Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64.
26. Matulonis U, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, et
al. Long-term safety and secondary efficacy endpoints in the
ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian
cancer. Gynecologic Oncology. 2021 08/01;162:S24-S5.
27. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al.
Maintenance olaparib for patients with newly diagnosed advanced ovarian
cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 2021 Dec;22(12):1721-31.
28. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I,
Pfisterer J. Role of surgical outcome as prognostic factor in advanced
epithelial ovarian cancer: a combined exploratory analysis of 3
prospectively randomized phase 3 multicenter trials: by the
Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe
Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux
Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009 Mar
15;115(6):1234-44.
29. Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, et
al. Ten-year survival after epithelial ovarian cancer is not associated
with BRCA mutation status. Gynecol Oncol. 2016 Jan;140(1):42-7.
30. Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, et al. The First Nationwide
Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in
Chinese Ovarian Cancer Patients. Int J Gynecol Cancer. 2017
Oct;27(8):1650-7.